Get access to our best features

Get access to our best features

Published 1 year ago

'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Summary by Ground News

The provision is known as skinny labeling, which refers to a move by a company that seeks regulatory approval to market a generic or biosimilar medicine. By doing so, the company seeks to avoid lawsuits in which the brand-name manufacturer could claim patent infringement. Medicare saved $1.5 billion from 2015 to 2020, or nearly 5% of the $30.2 billion spent by the health care program.

0 Articles

0 Articles

All

Left

Center

Right

'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Skinny labeling on biosimilar drugs saved Medicare $1.5 billion between 2015 and 2020 on just five medicines during that period.

1 year ago·Boston, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

STAT

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.